The APIIC is Strengthening Domestic Production of Active Pharmaceutical Ingredients (API) Through Advanced Manufacturing

Our nation’s over-reliance on foreign-sourced API has created both a public health and national security risk.  The APIIC is de-risking the return of API production to the U.S.

Continuous Flow Manufacturing

The continuous flow manufacturing process can significantly improve drug quality, address shortages of essential medicines, accelerate time to market, and strengthen the overall manufacturing competitiveness of the U.S.

WHO WE ARE

Driving Innovation, Delivering U.S.-Manufactured APIs 

The API Innovation Center (APIIC) is a non-profit organization dedicated to enabling the delivery of market-competitive commercial supply of U.S.-made Active Pharmaceutical Ingredients (APIs) to address critical needs in the healthcare supply chain while fostering job growth throughout the St. Louis region.  

Scientist working in the laboratory

The APIIC is a membership-based organization comprised of a network of companies, academic and research institutions, experts and startups spanning the API advanced manufacturing supply chain.

The Lomustine Project

Solving the Lomustine API Crisis for Glioblastoma Patients 

The APIIC’s initial project is the U.S. production of lomustine, a chemotherapy drug used to treat glioblastoma, the most common and aggressive form of brain cancer. There is currently no U.S. source of lomustine. According to the Society for Neuro-Oncology, “the field of neuro-oncology is in the midst of a crisis with lomustine.” The APIIC is working in partnership with Continuity Pharma and the Glioblastoma Foundation to resolve the lomustine crisis utilizing the advanced technologies of continuous flow manufacturing.

News & Updates

Keep Up to Date on Our Latest

Get In Touch

Contact Us Today

Address

4240 Duncan Ave., Suite 200
St. Louis, MO 63110